Browse drugs

…s Adult patients (>18 years) prescribed at least four cycles of oxaliplatin, cisplatin, docetaxel or paclitaxel were clinically assessed an…

…ounded 60 bags of 19 different drugs, including 5-fluorouracil, bevacizumab, carboplatin, cisplatin, cyclophosphamide, docetaxel, doxorubic…

…uorouracil, cisplatin+fluorouracil and oxaliplatin+leucovorin + fluorouracil regimens were administered to 46 (67%), 4 (6%) and 19 (27%) pat…

…arms (n=8,684 patients) with anti-PD-1/PD-L1 agents (nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, cemiplimab) for adult soli…

…17;389(10066):255–265.Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Eng…

… patients. High-risk patients exhibited enhanced sensitivity to dasatinib, docetaxel, erlotinib, and gefitinib ( figure 1).Conclusions Th…

…responses were associated with favorable clinical outcomes with ipilimumab.4 Tertiary lymphoid structures (TLS) are aggregates of T cells,…

…by cemiplimab 350 mg IV on Day 5, or single-agent chemotherapy (vinorelbine, gemcitabine, or docetaxel). The primary endpoint is overall su…

…t for patients resistant to immune checkpoint inhibitors (ICI). Ateganosine (THIO; 6-thio-2’-deoxyguanosine) is recognized by telomerase an…

…, et al. KEYNOTE-689: phase 3 study of adjuvant and neoadjuvant pembrolizumab combined with standard of care (SOC) in patients with resectabl…

… reduction in NK and B cells. When 177Lu-PSMA was combined with pembrolizumab, we saw dynamic changes in non-Treg T cell subsets (CD4+ and CD…

… as well as pathway analysis using MsigDB. Patient outcomes for docetaxel and atezolizumab were assessed in OAK and POPLAR clinical trial…